NCT04101435已完成3 期
Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) in Healthy Subjects Aged 3 Years Old to 17 Years Old
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 174
- 主要终点
- Evaluate the immunogenicity profiles for influenza virus vaccine strains of the AdimFlu-S (QIS) by seroconversion rate
研究概览
简要总结
The purpose of this study was to evaluate the antibody response to each of the four influenza vaccine strains included in the study vaccine, as measured by hemagglutination inhibition (HAI) at 4 weeks after the last dose of the study vaccine in young subjects aged between 3 years old and 17 years old.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Boys or girls aged 3 years old to 17 years old on the day of first vaccination;
- •Subject and/or parents(s)/legal guardian(s) must be willing to comply with planned study procedures and be available for all study visits;
- •Subject must be in good physical health on the basis of medical history, physical examination;
- •Subject and/or parents(s)/legal guardian(s) must read and signed the study-specific informed consent prior to initiation of any study procedure.
排除标准
- •Main exclusion criteria:
- •Subjects received influenza vaccine (Trivalent and/or Quadrivalent) within 6 months prior first vaccination.
- •History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication;
- •Personal or family history of Guillain-Barré Syndrome;
- •An acute febrile illness within 1 week prior to vaccination;
- •Current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours prior to vaccination;
- •Subjects with influenza-like illness as defined by the presence of fever (temperature >38ºC) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;
- •Female subjects who were pregnant, lactating or likely to become pregnant during the study; Women of childbearing potential disagreed to use an acceptable method of contraception (e.g., hormonal contraceptives, IUD, barrier device or abstinence) throughout the study;
- •Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent;
- •Immunodeficiency, or under immunosuppressive therapies;
- •Receipt of live virus vaccine within 1 month prior to study vaccination or expected to receive vaccination before the last blood sampling for immunogenicity evaluation;
- •Receipt of any inactivated vaccine within 2 weeks prior to study vaccination or expected to receive vaccination before the last blood sampling for immunogenicity evaluation;
- •Receipt of any blood products, including immunoglobulin from 3 months before first vaccination to the last blood sampling for immunogenicity evaluation;
- •Underlying condition in the investigators' opinion might interfere with evaluation of the vaccine.
- •Treatment discontinuation
- •Withdrawal criteria i. Subject/Subject's guardians decided to withdraw consent. ii. Lost to follow-up. iii. Administration of prohibited medication/treatment/vaccine. iv. Any pathological event, clinical adverse event, or any change in the subject's status giving indication to the pediatrician that further participation in the study might not be the best interests of the subject, according to investigator's discretion.
- •Contraindications to second vaccination
- •Subject with any of the following criteria might be contraindicated to take the second vaccination:
- •i. Had any Grade 3 or Grade 4 adverse reaction within 7 days after first dose. ii. Had any SAE related to first dose during the follow-up of first dose. iii. Any situations met the exclusion criteria, except the exclusion criterion (1) and (8).
研究组 & 干预措施
Group A
Experimental
Aged 3 to 8 years old vaccine naïve subject (without prior seasonal influenza vaccine exposure)
干预措施: AdimFlu-S (QIS) (Biological)
Group B
Active Comparator
Aged 3 to 8 years old vaccine non-naïve subject (with prior seasonal influenza vaccine exposure)
干预措施: AdimFlu-S (QIS) (Biological)
Group C
Experimental
Aged 9 to 17 years old subject
干预措施: AdimFlu-S (QIS) (Biological)
结局指标
主要结局
Evaluate the immunogenicity profiles for influenza virus vaccine strains of the AdimFlu-S (QIS) by seroconversion rate
时间窗: Change from baseline for anti-hemaglutinin antibodies at 28 days post immunization
The primary endpoint of immunogenicity evaluation was the seroconversion rate
Evaluate the immunogenicity profiles for influenza virus vaccine strains of the AdimFlu-S (QIS) by geometric mean folds increase
时间窗: Change from baseline for anti-hemaglutinin antibodies at 28 days post immunization
The primary endpoint of immunogenicity evaluation was the geometric mean folds increase
次要结局
- Evaluate the immunogenicity profiles for influenza virus vaccine strains of the AdimFlu-S (QIS) by seroprotection rate(Change from baseline for anti-hemaglutinin antibodies at 28 days post immunization)
- Evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events of the AdimFlu-S (QIS)(In regard to the long term safety of the study vaccine, the significant and/or serious adverse event(s) will be recorded during the 6 months follow up after the scheduled last vaccination)
研究者
相似试验
已完成
4 期
The Safety and Immune Response to Influenza Vaccination in Pregnant WomenInfluenzaNCT01514708Adimmune Corporation46
已完成
4 期
Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months OldInfluenzaNCT01355172Adimmune Corporation59
已完成
不适用
Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly SubjectsInfluenzaNCT01411358Adimmune Corporation128
已完成
4 期
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly SubjectsInfluenzaNCT01752881Adimmune Corporation130
已完成
4 期
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years OldInfluenzaNCT01356342Adimmune Corporation181